Skip to content
preclinicalImmune & Inflammation

Bronchogen

Also known as: Ala-Glu-Asp-Leu, AEDL tetrapeptide, Bronchial bioregulator

Bronchogen (Ala-Glu-Asp-Leu) is a synthetic tetrapeptide bioregulator targeting bronchial and respiratory tissue. Part of Khavinson's bioregulator family, it is proposed to modulate gene expression in bronchial epithelium and smooth muscle cells. Preclinical research reports improvements in bronchial mucosal immune function and respiratory epithelium integrity in aged animal models.

2 cited references·2 researched benefits

Quick Answer

Bronchogen (Ala-Glu-Asp-Leu) is a synthetic tetrapeptide bioregulator targeting bronchial tissue. It is proposed to modulate gene expression in bronchial epithelium and smooth muscle, supporting mucosal immunity and respiratory function. Part of the Khavinson bioregulator family, it remains a preclinical research compound studied primarily in Russian laboratories for age-related respiratory decline.

Key Facts

Mechanism
Bronchogen reportedly interacts with DNA regulatory elements in bronchial smooth muscle cells and mucosal epithelium, modulating expression of genes involved in bronchial reactivity, mucus production, and local immune defense (secretory IgA, antimicrobial peptides). The leucine residue may interact with hydrophobic DNA groove regions for binding specificity.
Research Status
preclinical
Half-Life
~1–2 hours (estimated)
Molecular Formula
C₁₆H₂₇N₃O₈
Primary Use
Immune & Inflammation
Table of Contents

Benefits

  • Bronchial support — may improve respiratory epithelium function and mucosal immunitypreliminary
  • Anti-inflammatory — preclinical data suggests reduction in bronchial inflammation markerspreliminary

Dosage Protocols

RouteDosage RangeFrequencyNotes
Research use only10–100 mcgVariablePreclinical research compound. No approved therapeutic dosing.

Medical disclaimer

Dosage information is provided for educational reference only. Always follow your prescriber's instructions and consult a qualified healthcare provider before starting any peptide protocol.

Side Effects

  • No significant adverse effects reported in preclinical studiesrare

Frequently Asked Questions

Can Bronchogen help with asthma or COPD?
There is no clinical evidence supporting Bronchogen for asthma or COPD. It has been studied only in preclinical models. For respiratory diseases, established therapies (inhaled corticosteroids, bronchodilators, biologics) have extensive clinical evidence. Bronchogen should be considered experimental.

References

  1. 1
    Bronchial peptide bioregulators: effects on respiratory epithelium(2007)
  2. 2
    Tissue-specific peptide bioregulation in respiratory tract aging(2011)PubMed ↗

Latest Research

Last updated: 2026-02-19